HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.

Abstract
Mucopolysaccharidosis VI (MPS VI) is an inheritable, clinically heterogeneous lysosomal storage disorder that develops due to a deficiency in the arylsulfatase B (ASB) enzyme. This deficiency impairs the stepwise degradation of glycosaminoglycans (GAGs) resulting in the accumulation of partially degraded GAGs in tissues and organs throughout the body. A relatively novel therapy for MPS VI is enzyme replacement therapy (ERT) with human recombinant ASB (galsulfase). This manuscript gives an overview of all clinical trials that have evaluated the efficacy and safety of ERT with galsulfase in patients with MPS VI to date and discusses the outcome of these trials.
AuthorsPaul Harmatz
JournalThe Turkish journal of pediatrics (Turk J Pediatr) 2010 Sep-Oct Vol. 52 Issue 5 Pg. 443-9 ISSN: 0041-4301 [Print] Turkey
PMID21434527 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Recombinant Proteins
  • N-Acetylgalactosamine-4-Sulfatase
  • galsulfase
Topics
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Drug-Related Side Effects and Adverse Reactions
  • Enzyme Replacement Therapy
  • Female
  • Humans
  • Male
  • Mucopolysaccharidosis VI (drug therapy)
  • N-Acetylgalactosamine-4-Sulfatase (adverse effects, therapeutic use)
  • Recombinant Proteins (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: